Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 and Gemtuzumab Ozogamicin in Relapsed/Refractory Pediatric AML
NCT04915612Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2021
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies, Targeted Liposomes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of daunorubicin + cytarabine liposome and gemtuzumab ozogamicin in acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose at 28 days and Incidence of Adverse Events at 28 days. Started May 2021; status: completed.
02
Drugs
daunorubicin + cytarabine liposomegemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04915612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04915612.